EVEREST MED.LTD DL-0001 Total Liabilities
EVEREST MED.LTD DL-0001 total liabilities. Based on the latest financial reports, EVEREST MED.LTD DL-0001 (6HN) has total liabilities worth €3.22 Billion EUR (≈ $3.76 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EVEREST MED.LTD DL-0001 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of EVEREST MED.LTD DL-0001 (2021–2025)
Total liabilities of EVEREST MED.LTD DL-0001 from 2021 to 2025. This chart illustrates how EVEREST MED.LTD DL-0001's total liabilities have evolved over time, based on quarterly financial data.
EVEREST MED.LTD DL-0001 Competitors by Total Liabilities
The table below lists competitors of EVEREST MED.LTD DL-0001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fermi Inc.
NASDAQ:FRMI
|
USA | $731.48 Million |
|
Palfinger AG
VI:PAL
|
Austria | €1.23 Billion |
|
Guizhou Qianyuan Power Co Ltd
SHE:002039
|
China | CN¥8.60 Billion |
|
Donnelley Financial Solutions Inc
NYSE:DFIN
|
USA | $446.90 Million |
|
Cymbria Corporation
TO:CYB
|
Canada | CA$138.94 Million |
|
Darbond Technology Co. Ltd. A
SHG:688035
|
China | CN¥1.03 Billion |
|
Shelly Group SE
XETRA:SLYG
|
Germany | €53.91 Million |
|
Vizsla Silver Corp.
TO:VZLA
|
Canada | CA$537.93 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down EVEREST MED.LTD DL-0001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 6HN asset base.
Liquidity & Leverage Metrics
EVEREST MED.LTD DL-0001 Total Liabilities Ratios Explained
EVEREST MED.LTD DL-0001 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EVEREST MED.LTD DL-0001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EVEREST MED.LTD DL-0001 (2021–2025)
The table below shows the annual total liabilities of EVEREST MED.LTD DL-0001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.53 Billion ≈ $1.79 Billion |
+72.81% |
| 2024-12-31 | €886.05 Million ≈ $1.04 Billion |
+10.19% |
| 2023-12-31 | €804.10 Million ≈ $940.08 Million |
-16.26% |
| 2022-12-31 | €960.25 Million ≈ $1.12 Billion |
+27.38% |
| 2021-12-31 | €753.83 Million ≈ $881.30 Million |
-- |
About EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocyc… Read more